Targeted Alpha Therapies and NETs – Dr Andrew Henderson
A recorded Zoom-In session with Dr Andrew Henderson on targeted alpha therapies for neuroendocrine tumours.
Written by NECNZ team
This resource has no body content.
Related resources
More like this →
SCAN 2025 – NET patient survey (New Zealand)
The New Zealand reading of the global SCAN 2025 survey of neuroendocrine cancer patients and clinicians – how our care compares with the world.
BookletPatient Guide
This booklet has been developed to provide information about neuroendocrine tumours (NETs) for patients and their families.
MEN1 syndrome (Multiple Endocrine Neoplasia type 1)
MEN1 is a rare inherited condition that causes tumours in the endocrine glands – the parathyroids, pituitary and pancreas. What it is, what causes it, and how it is diagnosed.
Types of scans for NET Cancers
There are various types of scans that may or may not be suitable for your type of NETs. Here is a summary of some scans you might encounter.